

tered, but the accumulation of patient data collected every year was analyzed¹. About 81% of the registered patients have been followed continuously in the following year during the whole observation period. Information about the occurrence of malignancy was collected by the physician's declaration by reference to medical records or medical referral letters. The study was reviewed and approved by the research ethics committees of the National Hospital Organization and each participating hospital.

To adjust for the differences in population composition and to compare the incidence of malignancy between patients with RA and the general population, standardized incidence rates (SIR) were calculated. The SIR was the ratio of the observed number of malignancies from the cohort and the expected number in the general age-matched and sex-matched Japanese population. Data on the incidence of malignancies in the general population were obtained from the Center for Cancer Control and Information Services, National Cancer Center, Japan⁸. Lymphoma, mainly Hodgkin's and non-Hodgkin's lymphoma, corresponds to C81–85 and C96 as coded in the *International Statistical Classification of Diseases and Related Health Problems*, 10th ed. The 95% CI of the SIR was calculated by referring to the observed number of malignancies as a Poisson variable and its related 95% interval obtained from statistical tables. Annual SIR and 95% CI of lymphoma and overall malignancies were calculated by reference to incidence in the general Japanese population in the same year (for SIR until 2008) or in 2008 (for SIR after 2008).

To identify risk factors for the development of lymphoma, each patient's data in the year before the onset of lymphoma (2002–2011) were used for univariate and multivariate analysis with multiple logistic regression. The data of the patient-years after the onset of lymphoma were excluded in this analysis. To select significant variables for multivariate analysis, stepwise regression through backward elimination was applied to the following variables: age, sex, RA disease duration, Steinbrocker stage score, global functional status, Disease Activity Score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) or C-reacting protein (CRP), and use of nonsteroidal antiinflammatory drugs (NSAID), corticosteroids, methotrexate (MTX), tacrolimus, non-tacrolimus immunosuppressants (azathioprine, mizoribine, cyclophosphamide, and cyclosporine), anti-tumor necrosis factor (TNF) biologics (including infliximab, etanercept, adalimumab, and golimumab), and non-anti-TNF biologics (including tocilizumab and abatacept). In Japan, tacrolimus is the most common immunosuppressant in patients with RA and these biologics were all those that had been approved for RA by 2012. The stage of articular destruction was classified from radiographs of the hands based on the Steinbrocker classification (Steinbrocker stage)⁹. Global functional status was based on the classification by the American College of Rheumatology 1991 revised criteria¹⁰.

Between-group comparisons for univariate analysis were conducted using the Wilcoxon rank sum testing (with continuity correction) for numerical values or Fisher's exact test for proportions. Significant p values were those lower than 0.05.

RESULTS

Table 1 shows baseline characteristics of the cohort based on patient-years. Over 10 years (2003–2012), the cohort accumulated 66,953 patient-years (81.6% female patient-years and 18.4% male) from 45 hospitals and yielded 559 malignancies. These were found in 370 women (67%) and 179 men (33%). Nine patients had multiple malignancies simultaneously. The incidence rate of malignancies of all types in the cohort was 820 per 100,000 person-years (0.8%). Mean age and DAS28-ESR of all patients were 62.7 years and 3.63, respectively.

Differences in characteristics of patients with or without malignancy are shown in Table 2, indicating that accumu-

Table 1. Baseline characteristics of the entire cohort based on patient-years. Values are % unless otherwise specified.

Characteristic	Value
No. patient-yr	66,953
Female sex	81.6
Age, yrs, mean ± SD	62.7 ± 12.6
Disease duration, yrs, median (IQR)	10 (5–19)
DAS28-ESR, mean ± SD	3.63 ± 1.36
DAS28-CRP, mean ± SD	2.92 ± 1.23
Stage I/II/III/IV	19/27/20/34
Class 1/2/3/4	28/52/17/3
Treated with NSAID	57.6
Treated with corticosteroids, dose, mg/week (median)	54.1 (4.5)
Treated with MTX, dose, mg/week (median)	52.9 (6)
Treated with anti-TNF biologics	11.3
Treated with non-anti-TNF biologics	3.7
Treated with any IS	6.7
Treated with tacrolimus	6.0

Anti-TNF biologics consist of infliximab, etanercept, adalimumab, and golimumab. Non-anti-TNF biologics consist of tocilizumab and abatacept. Dose of corticosteroids was expressed in prednisolone equivalents. IS consist of tacrolimus, azathioprine, mizoribine, cyclophosphamide, and cyclosporine. IQR: interquartile range; DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; Stage: Steinbrocker stage score; Class: global functional status; NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate; anti-TNF: anti-tumor necrosis factor; IS: immunosuppressants.

lated patient-years with the onset of malignancy were greater for men (33% with malignancy vs 18% without malignancy, $p < 0.0001$), older patients (mean age 68.1 vs 62.7 yrs, respectively, $p < 0.0001$), and patients with higher age at onset of RA (mean age 54.8 vs 49.7 yrs, respectively, $p < 0.0001$) relative to those without malignancy.

The most frequent malignancy was lung cancer ($n = 89$, 16% of all malignancies), followed by gastric cancer ($n = 78$, 14%), breast cancer ($n = 66$, 12%), lymphoma ($n = 63$, 11%), and colon cancer ($n = 47$, 8%). Unlike the other malignancies, patients with lymphoma had onset of RA at a younger age (median 51.6 yrs with lymphoma vs 55.2 yrs with other malignancies, $p = 0.0406$) and had longer RA disease duration (median 12 yrs vs 10 yrs, respectively, $p = 0.0140$).

The total SIR of malignancies was 0.89 overall (95% CI 0.82–0.97), a significantly lower incidence than in the general population (Table 3). Thus, the SIR for gastric cancer in women (SIR 0.69, 95% CI 0.46–0.91), colon cancer in both sexes (SIR 0.71, 95% CI 0.51–0.91), pancreatic cancer in women (SIR 0.61, 95% CI 0.25–0.97), rectal cancer in both sexes (SIR 0.59, 95% CI 0.32–0.86), cancer of the kidney or urinary tract in men (SIR 0.35, 95% CI –0.13–0.82), liver cancer in both sexes (SIR 0.33, 95% CI 0.15–0.51), and leukemia in both sexes (SIR 0.37, 95% CI –0.05–0.79) were significantly lower than in the general population. However, in both sexes, the SIR of lymphoma (SIR 3.43, 95% CI 2.59–4.28) was significantly higher.

Table 2. Characteristics of patients with or without malignancy based on patient-years.

Characteristic	With Onset of:						Overall Malignancies, n = 549	Without Onset of Malignancy, n = 66,404
	Lung Cancer, n = 89	Gastric Cancer, n = 78	Breast Cancer, n = 66	Lymphoma, n = 63	Colon Cancer, n = 47			
Female, %	52*	46*	100*	71	68*	67*	82	
Age, yrs, mean (range)	69.6* (34–88)	70.1* (44–86)	62.7 (44–85)	67.7* (39–88)	72.7* (50–92)	68.1* (34–92)	62.7 (7–104)	
Age at onset of RA, yrs, mean (range)	58.8* (27–84)	59.1* (15–80)	50.7 (23–79)	51.6 (16–78)	58.7* (34–87)	54.8* (15–87)	49.7 (1–103)	
Disease duration of RA, yrs, median (range)	8* (0–49)	9 (0–57)	8 (0–39)	12* (3–55)	12 (0–43)	10 (0–57)	10 (0–72)	
Patients in Stage I or II, %	45	45	41	29	45	38	41	

* p < 0.05 versus all other patient-years. RA: rheumatoid arthritis; Stage: Steinbrocker stage score.

Table 3. Types (ICD-10 codes), observed and expected numbers of malignancies, and their SIR with 95% CI. No information about the incidence of breast cancer in men was provided. The other 15 malignancies recorded in women and 3 in men, including duodenal cancer and tongue cancer, are not shown.

Type of Malignancy, ICD-10 Code	O/E	Female		O/E	Male		O/E	Total	
		SIR	95% CI		SIR	95% CI		SIR	95% CI
Overall malignancies	373/414.49	0.90 [†]	0.81–0.99	186/211.40	0.88	0.75–1.01	559/625.90	0.89 [†]	0.82–0.97
Lung, C33–C34	46/41.92	1.10	0.78–1.41	43/33.32	1.29	0.90–1.68	89/75.24	1.18	0.94–1.43
Stomach, C16	36/52.36	0.69 [†]	0.46–0.91	42/41.10	1.02	0.71–1.33	78/93.46	0.83	0.65–1.02
Breast, C50	66/79.33	0.83	0.63–1.03	0/					
Lymphoma, C81–C85, C96	45/12.92	3.48*	2.46–4.50	18/5.42	3.32*	1.79–4.85	63/18.35	3.43*	2.59–4.28
Colon, C18	32/46.91	0.68 [†]	0.45–0.92	15/19.44	0.77	0.38–1.16	47/66.35	0.71 [†]	0.51–0.91
Prostate, C61				22/27.34	0.80	0.47–1.14			
Pancreas, C25	11/18.13	0.61 [†]	0.25–0.97	7/7.75	0.90	0.23–1.57	18/25.88	0.70	0.37–1.02
Bladder, C67	12/5.50	2.18	0.95–3.41	6/6.65	0.90	0.18–1.62	18/12.15	1.48	0.80–2.17
Rectum, C19–C20	14/18.56	0.75	0.36–1.15	4/12.05	0.33 [†]	0.01–0.66	18/30.61	0.59 [†]	0.32–0.86
Uterus body, C54	17/15.11	1.13	0.59–1.66						
Uterus cervix, C53	16/9.93	1.61	0.82–2.40						
Kidney/urinary tract, C64–C66, C68	14/8.23	1.70	0.81–2.59	2/5.79	0.35 [†]	–0.13–0.82	16/14.02	1.14	0.58–1.70
Gallbladder/bile duct, C23–C24	9/12.83	0.70	0.24–1.16	4/5.33	0.75	0.02–1.49	13/18.16	0.72	0.33–1.10
Liver, C22	8/23.69	0.34 [†]	0.10–0.57	5/15.95	0.31 [†]	0.04–0.59	13/39.64	0.33 [†]	0.15–0.51
Skin, C43–C44	9/7.92	1.14	0.39–1.88	3/3.25	0.92	–0.12–1.97	12/11.17	1.07	0.47–1.68
Esophagus, C15	4/4.78	0.84	0.02–1.66	5/8.61	0.58	0.07–1.09	9/13.39	0.67	0.23–1.11
Ovary, C56	7/11.66	0.60	0.16–1.04						
Thyroid, C73	7/10.79	0.65	0.17–1.13	0/1.12			7/11.91	0.59	0.15–1.02
Laryngeal, C32	1/0.61	1.65	–1.58–4.87	4/2.44	1.64	0.03–3.25	5/3.04	1.64	0.20–3.08
Leukemia, C91–C95	1/5.52	0.18 [†]	–0.17–0.54	2/2.54	0.79	–0.30–1.88	3/8.06	0.37 [†]	–0.05–0.79
Multiple myeloma, C88–C90	2/3.81	0.52	–0.20–1.25	0/1.51			2/5.32	0.38 [†]	–0.14–0.90
Brain, C70–C72	1/2.94	0.34	–0.33–1.01	1/1.00	1.00	–0.96–2.97	2/3.94	0.51	–0.20–1.21

* SIR significantly higher than 1. [†] SIR significantly lower than 1. ICD-10: *International Statistical Classification of Diseases and Related Health Problems*, 10th ed; SIR: standardized incidence rate; O: observed number; E: expected number.

When looking at the transition from 2003 to 2012 (Figure 1), there were changes in treatment over the years, with the use of MTX increasing from about 36.6% of all registered patients in 2003 to 62.0% in 2012. Similarly, use of biologics increased from 0.5% to 22.9% and tacrolimus from very few to 9.7%. In contrast, the use of corticosteroids decreased from 62.5% to 45.3% of patients and NSAID from 73.3% to 45.5%. Concerning disease activity of RA, the percentage of patients with DAS28-ESR less than 3.2 (corresponding to low disease activity or remission) increased from 25% to 54%.

Nevertheless, as shown in Figure 2, annual SIR of

lymphoma and overall malignancies remained steady at about 4 and 1, respectively. There was no tendency for the annual SIR of other malignancies, such as lung, gastric, breast, colon, and rectal cancer, to either increase or decrease (data not shown).

To identify risk factors associated with the increased frequencies of lymphomas, data from individual patients in the year before lymphoma onset (2002–2011) were analyzed. First, we examined correlations between the onset of lymphoma and DAS28-ESR or -CRP at a single measurement in the preceding year, which were not significant (p = 0.8811 for DAS28-ESR or p = 0.6444 for




Figure 1. Changes in medication usage and patients with remission or low disease activity of RA. Each bar represents the annual rate of patients with disease activity score in DAS28-ESR lower than 3.2. The use rate of NSAID in 2012 was 45.5% and that of corticosteroids was 45.3%. RA: rheumatoid arthritis; DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate; NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate.




Figure 2. Annual SIR and 95% CI of lymphoma (broken line) and overall malignancies (solid line). The SIR of lymphoma are stable at about 4 and those of overall malignancies at 1. SIR: standardized incidence rate.

DAS28-CRP). Second, stepwise regression was used to screen variables. In variables including background characteristics or medications, only the following variables were selected as significant for multivariate analysis: age, use of MTX, and use of tacrolimus. Third, when performing multivariable analysis, we added the following variables for clinical concern: sex and use of NSAID, corticosteroids,

non-tacrolimus immunosuppressants, and any biologics (anti-TNF and non-anti-TNF). As shown in Table 4, higher age (OR 1.04 per an additional yr of age), use of MTX (OR 3.5, 95% CI 2.0–6.3), and use of tacrolimus (OR 3.9, 95% CI 1.9–7.4) were significantly associated with the onset of lymphoma in the next year. Tacrolimus was often used for patients with RA in Japan, while the other immunosuppres-

Table 4. Risk factors for lymphoma by multivariable analysis.

Risk Factor	OR	95% CI	p
Age	1.04*	—	0.0032
Male sex	1.6	0.9–2.8	0.0880
NSAID	0.7	0.4–1.1	0.1048
Corticosteroids	0.8	0.5–1.4	0.4523
MTX	3.5	2.0–6.3	< 0.0001
Tacrolimus	3.9	1.9–7.4	< 0.0001
Non-tacrolimus IS	6.8	0.4–32.8	0.0608
Biologics	0.9	0.4–1.9	0.8731

* Per an additional year of age. NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate; IS: immunosuppressants.

sants were not (Table 1). Non-tacrolimus immunosuppressants (azathioprine, mizoribine, cyclophosphamide, or cyclosporine) also had high OR (6.8) but showed no statistical significance, probably because of the paucity of patients receiving them (0.5% of total patient-yrs in this analysis). Concurrent use of MTX and tacrolimus presented no additive effect for developing lymphoma (data not shown).

We observed that 46 (73%) and 10 (16%) of 63 patients who developed lymphoma had received MTX or tacrolimus in the preceding year, respectively, while MTX or tacrolimus was used in 50% and 5% of all patient-years, respectively ($p = 0.0003$ for MTX and $p = 0.0010$ for tacrolimus). No significant correlation was found between the onset of lymphoma and the dose of MTX in the preceding year (data not shown).

DISCUSSION

Advances in the treatment and management of patients with RA have contributed not only to the reduction of their symptoms and the improvement of function and quality of life, but also to increased life expectancy. However, malignancy is emerging as one of the least tractable, unexpected, life-threatening complications during the course of RA. It is not clear whether the overall incidence of malignancies in patients with RA is higher^{11,12,13}, lower^{14,15}, or the same as in the general population^{16,17}. Because the incidence of each type of malignancy differs according to regional or racial features, the overall incidence of malignancies differs from study to study. With respect to the contemporary general Japanese population, breast cancer is the most frequent malignancy in women, followed by colon, gastric, and lung cancer. In men, gastric cancer is the most common cancer, followed by lung or colon cancer⁸. Our 10 years' observation of Japanese patients with RA revealed a slightly but significantly reduced overall incidence of malignancies of any type (SIR 0.89), but excess lymphoma compared with the age-matched and sex-matched Japanese population. Fewer malignancies overall resulted from reduced frequencies of several types, including colorectal and liver

cancer. These results almost agree with the latest research from East Asia (Taiwan)¹⁵. Although the sample size of our cohort was not small, annual fluctuations of the numbers of different malignancies did occur. However, these had little influence on the SIR over the entire observation period. Thus, a conservative interpretation of the annual SIR for malignancies overall (Figure 2) is that their incidence in patients with RA is similar to that in the general population.

Less colorectal cancer in patients with RA has previously been reported in epidemiological studies^{11,13,14,15,16,18}. This might be the result of using NSAID, the inhibitory effect of which on colorectal cancer was confirmed by experimental animal studies¹⁹ and metaanalysis of clinical research²⁰. Additionally, as in a study in Taiwan (SIR 0.87, 95% CI 0.75–1.00)¹⁵, we found decreased liver cancer. The rarity of these cancers can be explained by the finding that NSAID, which were used in about 60% of all patient-years, induced apoptosis of such cancer cells by means of cyclooxygenase 2 suppression^{21,22}. If this is so, the recent decreased use of NSAID in patients with RA could lead to increased colorectal cancer in the future; however, such a tendency is not detectable to date (data not shown).

Several reports have noted excess lung cancer in patients with RA, although not as frequently as lymphoma^{11,12,13,23}. We also saw a tendency for increased lung cancer, but this was not statistically significant. The reasons for the difference between our results and the earlier reports cannot be determined because of the lack of information in our study about risk factors, such as smoking history and the presence of interstitial lung disease (ILD), which would be associated with the development of lung cancer.

Lymphoma, particularly non-Hodgkin's lymphoma, is well known to develop in patients with RA. The SIR of 3.43 for lymphoma in our cohort is consistent with results of earlier studies that reported a SIR of lymphoma ranging from about 2 to 6^{11,12,13,15,16,18}. Moreover, currently, most patients with RA are treated with MTX, biologics, or disease-modifying antirheumatic drugs, all of which might contribute to the development of lymphoma. The association between RA *per se* and lymphoma was established by the finding that lymphoma incidence was increased in patients with RA even before MTX was approved by the US Food and Drug Administration in 1988^{24,25,26,27}. Further, a case-control study with quantitative analysis of cumulative disease activity of RA by Baecklund, *et al* revealed an association between disease activity and the development of lymphoma²⁸. That analysis was critical because longterm disease activity of RA was taken into account and channeling bias was excluded. Thus, the tendency for physicians to administer potent antirheumatic drugs such as MTX and biologics to patients with severe RA who may then be at a higher risk of developing lymphoma was excluded. In our study, we found that patients who developed lymphoma had had a significantly longer RA disease duration (Table 2),

supporting the existence of a relationship between RA cumulative disease activity and the development of lymphoma. On the other hand, the results of Baecklund, *et al* yielded no statistically significant associations between the development of lymphoma and the use of antirheumatic drugs, including MTX²⁸. However, that could have been because of the small number of patients who received MTX (5%) in their study.

Subsequent RA case series have documented spontaneous remission of lymphoma after withdrawal of MTX, implying an association between MTX and lymphoma²⁹. Many such cases are diffuse large B cell lymphomas positive for Epstein-Barr virus (EBV)^{30,31,32,33,34}. Possible mechanisms for the development of EBV-related lymphoma in addition to some property of RA *per se*^{34,35} are, therefore, the reduction of the ability to prevent EBV infection by MTX^{36,37}. In agreement with a prospective cohort study³⁸, we showed in the present epidemiological study that MTX use was a risk factor for the development of lymphoma even after adjustment for several variables, including age, sex, and use of other antirheumatic drugs. Meanwhile, we were unable to demonstrate an association between lymphoma and RA disease activity in our study. Although DAS28 assessed at a single measurement in the year before the onset of lymphoma was taken as a measure of disease activity, this might not represent longterm disease activity as in the study of Baecklund, *et al*²⁸. Given that not only MTX, but also RA disease activity alone, is associated with the development of lymphoma, the efficacy of MTX in also preventing lymphoma by reducing disease activity should be evaluated.

We did not find any significant correlations between the development of lymphoma and the use of biologics, which is consistent with previous metaanalyses^{39,40}. No other antirheumatic drugs have been suggested to induce malignancy except for immunosuppressants, such as azathioprine^{23,28,41}, for which the risk is difficult to ascertain because so few patients with RA are treated with them. In addition to MTX, the use of tacrolimus was significantly associated with the development of lymphoma in our multivariate analysis. Azathioprine was assumed to be a candidate lymphoma-inducer in patients with inflammatory bowel disease⁴² through its effects on mutation and DNA repair⁴³. However, the risk of lymphoma development associated with oral tacrolimus in patients with autoimmune diseases has not been evaluated because this drug is approved for RA in only a few countries worldwide and insufficient data exist. Tacrolimus, a calcineurin inhibitor, is primarily used in patients with organ transplants, in whom an increased risk of lymphoma has been noted⁴⁴. Our results are supported by a report of a small number of Japanese patients with autoimmune diseases who were thought to have developed tacrolimus-induced lymphoma⁴⁵. It can be hypothesized that oral tacrolimus is associated with the

development of lymphoma through systemic immune suppression in patients with RA for the same reason as in patients with transplants, despite the low initial dose of the drug.

Although our study demonstrated that the use of MTX or tacrolimus means a significant risk for developing lymphoma in patients with RA, the risk could be reduced by some confounding factors such as reduced RA disease activity. A characteristic of our database, NinJa, is to provide an overview as well as annual changes of all patients' profiles, which can present data for an interpretation of the relationship. Of note, the following 3 trends were observed. First, annual SIR of lymphoma have not changed over the survey period (Figure 2). Second, the proportion of patients receiving MTX or tacrolimus has been increasing in those 10 years. Third, the number of patients with remission or low disease activity has been increasing over the years¹ (Figure 1). The stable annual SIR of lymphoma might possibly result from a balance between increased lymphoma caused by elevated use of MTX or tacrolimus, but decreased incidence from reduced RA disease activity. Otherwise, assuming that there is a time lag between the administration of those drugs and lymphoma development, the SIR of lymphoma would increase further in future. While the use of MTX or tacrolimus may carry a certain risk for lymphoma development, it should be emphasized that they are now essential for RA disease control.

The limitations of our present study are related to its open prospective cohort registry nature and the smaller proportion of followed-up patients relative to single-center cohorts. That is, only malignancies that the patients developed while attending the hospitals participating in the NinJa registry were recorded. In contrast to single institutional cohorts, which have low dropout rates with close followup of patients, our nationwide multiinstitutional cohort represents an overview of all Japanese patients with RA and has the advantage of excluding biases, such as center effect, ethnicity, and socioeconomic status. Because a single institute specializing in rheumatology tends to accumulate referral patients with poorly controlled RA and to transfer those who do not require active treatment to regional hospitals or family doctors, such single-center studies may focus on unrepresentative, relatively young patients with active and severe RA. Indeed, patients in a large Japanese single institutional cohort were younger and had more active RA than those in our cohort¹³.

Other limitations of our study lie in the time between the onset of lymphoma and the administration period of a drug. We sought correlations between the onset of lymphoma and medication in the preceding year, on which the significance of the risk for lymphoma was based. The duration of the treatment or whether lymphoma developed during or after the drug administration period was not taken into account. In addition, evaluating the risk of malignancies, including

lymphoma, in patients with RA would require the prospective study to include detailed information for variables such as accumulated disease activity, comorbidity, and history of cancer, medication, and smoking. For instance, Sjögren syndrome vastly augments the risk for lymphoma⁵, just as ILD does for lung cancer. Smoking has been established as contributing to various malignancies, except for several cancers such as breast and prostate cancer, in the general population⁴⁶. Some studies noted an increased risk for smoking-related cancers in patients with RA⁴⁷ because smoking is a risk factor for RA *per se*⁴⁸, but other studies, including ours, have not. It is not well known whether smoking contributes to the development of such malignancies in patients with RA as in the general population.

Our present study demonstrated that patients with RA have no higher overall incidence of malignancies than the general population, but should be closely monitored for lymphoma development, which is more frequent. Older age, use of MTX, and use of tacrolimus in the preceding year were identified as risk factors for lymphoma development. In studying the risk for malignancy in patients with RA, it is important to discriminate between characteristics of RA (particularly longterm disease activity) and the influence of therapeutic or environmental factors and comorbidities. These influences still need to be investigated. Further work is required to elucidate the mechanisms responsible for increased lymphoma but decreased occurrence of several other malignancies in patients with RA.

ACKNOWLEDGMENT

We thank Mayumi Yokoyama (Sagamihara National Hospital) for secretarial assistance. We also thank Dr. Satoshi Kashiwagi (Amagasaki Medical Coop Hospital), Dr. Masao Katayama (Nagoya Medical Center, National Hospital Organization), Dr. Ryutaro Matsumura (Chiba East National Hospital, National Hospital Organization), Dr. Akira Okamoto (Himeji Medical Center, National Hospital Organization), Dr. Kota Shimada (Tokyo Metropolitan Tama Medical Center), and Dr. Yoshiki Shiohira (Tomishiro Chuo Hospital) for their support in data collection.

REFERENCES

- Saeki Y, Matsui T, Saisho K, Tohma S. Current treatments of rheumatoid arthritis: from the 'NinJa' registry. *Expert Rev Clin Immunol* 2012;8:455-65.
- Shinomiya F, Mima N, Nanba K, Tani K, Nakano S, Egawa H, et al. Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. *Mod Rheumatol* 2008;18:165-9.
- Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. *Scand J Rheumatol* 2010;39:360-7.
- Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. *Arthritis Rheum* 1994;37:481-94.
- Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. *Arch Intern Med* 2005;165:2337-44.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;62:2569-81.
- Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Jpn J Clin Oncol* 2013;43:328-36.
- Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. *J Am Med Assoc* 1949;140:659-62.
- Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. *Arthritis Rheum* 1992;35:498-502.
- Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. *Arthritis Res Ther* 2008;10:R45.
- Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. *Arthritis Rheum* 2011;63:352-8.
- Yamada T, Nakajima A, Inoue E, Tanaka E, Taniguchi A, Momohara S, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. *Rheumatol Int* 2011;31:1487-92.
- Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. *Arthritis Rheum* 1997;40:1580-6.
- Huang WK, Chiou MJ, Kuo CF, Lin YC, Yu KH, See LC. No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan. *Rheumatol Int* 2014;34:1379-86.
- Gridley G, McLaughlin JK, Ekblom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. *J Natl Cancer Inst* 1993;85:307-11.
- Kim YJ, Shim JS, Choi CB, Bae SC. Mortality and incidence of malignancy in Korean patients with rheumatoid arthritis. *J Rheumatol* 2012;39:226-32.
- Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. *Rheumatology* 2008;47:698-701.
- Berkel H, Holcombe RF, Middlebrooks M, Kannan K. Nonsteroidal antiinflammatory drugs and colorectal cancer. *Epidemiol Rev* 1996;18:205-17.
- Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. *Ann Intern Med* 2007;146:376-89.
- Huang DS, Shen KZ, Wei JF, Liang TB, Zheng SS, Xie HY. Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2. *World J Gastroenterol* 2005;11:204-7.
- Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. *Asian Pac J Cancer Prev* 2013;14:2201-5.
- Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. *Rheumatology* 2013;52:91-8.
- Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. *J Chronic Dis* 1978;31:691-6.
- Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer

- morbidity in rheumatoid arthritis. *Ann Rheum Dis* 1984;43:128-31.
26. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. *Am J Med* 1985;78:29-32.
 27. Symmons DP. Neoplasms of the immune system in rheumatoid arthritis. *Am J Med* 1985;78:22-8.
 28. Baecklund E, Iliadou A, Askling J, Ekblom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum* 2006;54:692-701.
 29. Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. *N Engl J Med* 1993;328:1317-21.
 30. Weiss LM, Chen YY, Liu XF, Shibata D. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. *Am J Pathol* 1991;139:1259-65.
 31. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. *J Clin Oncol* 1996;14:1943-9.
 32. Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. *J Rheumatol* 2007;34:322-31.
 33. Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. *Cancer Sci* 2010;101:1309-13.
 34. Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. *Eur J Haematol* 2013;91:20-8.
 35. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. *Annu Rev Immunol* 1997;15:405-31.
 36. Feng WH, Cohen JJ, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. *J Natl Cancer Inst* 2004;96:1691-702.
 37. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. *Clin Immunol* 2005;114:154-63.
 38. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. *Ann Rheum Dis* 2006;65:617-22.
 39. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. *JAMA* 2012;308:898-908.
 40. Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. *Clin Rheumatol* 2012;31:631-6.
 41. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. *Ann Rheum Dis* 1988;47:988-92.
 42. Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. *Am J Epidemiol* 2013;177:1296-305.
 43. Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. *Aliment Pharmacol Ther* 2010;32:119-30.
 44. Akar Özkan E, Özdemir BH, Deniz EE, Tunca MZ, Haberal M. Posttransplant lymphoproliferative disorder after liver and kidney transplant. *Exp Clin Transplant* 2014;12 Suppl 1:142-8.
 45. Sekiguchi Y, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, et al. Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease: a case report and review of the literature. *J Clin Exp Hematop* 2012;52:211-8.
 46. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. *Lancet Oncol* 2009;10:1033-4.
 47. Askling J, Forged CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. *Ann Rheum Dis* 2005;64:1421-6.
 48. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. *Ann Rheum Dis* 2003;62:835-41.